人工抗体治疗癌症

技术进步和层级製药公司日益增长的兴趣推动了工程抗体的成长

这项研究分析了癌症工程抗体疗法的出现，并检验了推动其采用的因素。单株抗体的限制正在推动对新形式的需求。该公司正在开发多特异性抗体，例如双特异性和三特异性抗体，以及抗体片段，例如 Fab 和 VHH。这些工程抗体旨在同时结合多个靶点，从而提高疗效并克服肿瘤抗药性。创新的工程技术使研究人员能够实现更好的 PK/PD，包括延长半衰期和降低免疫抗原性。对工程抗体的需求也促使层级製药公司透过与领先的开发商合作并将多特异性抗体添加到其产品组合中来扩展其治疗专业知识。开发人员还与基于人工智慧/机器学习的技术提供者合作，以增强他们的抗体产品。

这项研究确定了不同的抗体形式并检验了它们在疾病领域的适用性。为了促进工程抗体形式的创建，我们重点介绍开发创新抗体发现、工程和开发服务的关键参与者。我们研究了驱动和抑制癌症工程抗体疗法成长的因素，并确定市场参与企业和相关人员应该利用的领域变化所带来的成长机会。

目录

策略要务

• 为什么成长如此困难？
• The Strategic Imperative 8（TM）
• 关键策略要务对癌症人工抗体疗法的影响
• 成长机会推动Growth Pipeline Engine（TM）
• 调查方法

成长机会分析

• 分析范围
• 分割

成长发电机

• 生长促进因子
• 成长抑制因素
• 需要人工抗体
• 目前抗体疗法的挑战
• 工程抗体疗法如何克服传统抗体的挑战

人工抗体疗法的演变

• 人工抗体形式 - 多特异性以获得更好的功效
• 研究癌症的 ADC
• 抗体片段/构建模组
• 分析不同抗体形式的不同构建模组
• 主要创新者
• 人工抗体开发的优先领域
• 抗体工程 - 开发更好抗体的策略
• BsAb 格式类型
• 多特异性抗体形式/工程技术
• 多特异性抗体在疾病领域的应用
• 癌症人工抗体的新兴创新
• BsAb 的免疫标靶策略
• Fab 的治疗效用
• 二价抗体片段F(ab')2的治疗效用
• scFv 的治疗效用
• 奈米抗体/VHH 的治疗效用
• 三特异性抗体的治疗效用
• 四特异性抗体的治疗效用
• 层级癌症製药公司的兴趣日益浓厚

抗体发现和开发

• 抗体开发平台-人源化小鼠
• 抗体开发平台-基因改造动物
• 实现高通量筛检的策略
• 微流体和基于液滴的技术的创新
• 单细胞分析的创新
• 功能筛检的创新
• 在抗体开发的各个方面利用 AI/ML

相关人员

• 最近用于抗体治疗开发的私人资金筹措

充满成长机会的世界

• 成长机会 1：改进优化
• 成长机会2：专注于新的抗体形式
• 成长机会 3：应用扩展

附录

• 技术成熟度等级 (TRL)：解释

下一步

Technology advances and increasing interest from Tier I pharmaceuticals are driving the growth of engineered antibodies

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and VHH. These engineered antibodies are created to have heightened efficacy and overcome tumor resistance by binding to multiple targets simultaneously. Innovative engineering technologies are helping researchers achieve better PK/PD with an enhanced half-life and less immunogenicity. The demand for engineered antibodies is also driving Tier I pharmaceuticals to collaborate with key developers to expand their therapeutic expertise by adding multispecific antibodies to their portfolios. Developers, on their part, are partnering with AI/ML-based technology providers to enhance their antibody offerings.

The study identifies the different antibody formats and examines their applicability across disease areas. It looks at the key players developing innovative antibody discovery, engineering, and development services to facilitate the creation of engineered antibody formats. The study examines the factors driving and restraining the growth of engineered antibody therapeutics for cancer and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.

Key Questions This Study Answers

1. What are the key drivers and restraints in the development of engineered antibodies?

2. What are the applications of engineered antibodies across different disease areas? What are the key focus areas of R&D efforts?

3. Which disease areas are seeing increased adoption?

4. What are the key innovative discoveries and engineering technologies?

5. What does the funding landscape look like?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Engineered Antibody Therapeutics for Cancer
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation

Growth Generator

• Growth Drivers
• Growth Restraints
• Need for Engineered Antibodies
• Challenges with Current Antibody Therapeutics
• How Engineered Antibodies Therapeutics Help Overcome the Challenges with Traditional Antibodies

Evolving Landscape of Therapeutic Engineered Antibodies

• Engineered Antibody Formats-Multi-specificity for Better Efficacy
• ADCs Explored for Oncology
• Antibodies Fragments/Building Blocks
• Analysis of Different Building Blocks for Different Antibody Formats
• Key Innovators
• Focus Area for Engineered Antibody Development
• Antibody Engineering-Strategies to Develop Better Antibodies
• Types of BsAb Formats
• Multispecifics Antibodies Formats/Engineering Technologies
• Multispecific Antibody Applications Across Disease Areas
• Emerging Innovations in Engineered Antibodies for Oncology
• Immune Targeting Strategies of BsAbs
• Therapeutic Utility of Fabs
• Therapeutic Utility of Bivalent Antibody Fragments F(ab')2
• Therapeutic Utility of scFvs
• Therapeutic Utility of Nanobodies/VHH
• Therapeutic Utility of Trispecific Antibodies
• Therapeutic Utility of Tetraspecific Antibodies
• Increasing Interest From Tier I Pharma Companies in Oncology

Antibody Discovery and Development

• Antibody Development Platforms-Humanized Mouse
• Antibody Development Platforms-Transgenic Animal
• Strategies to Achieve High Throughput Screening
• Innovation Around Microfluidics and Droplet-based Technologies
• Innovation Around Single Cell Analysis
• Innovation Around Functional Screening
• Use of AI/ML Across Different Aspects of Antibody Development

Stakeholder System

• Recent Private Funding for the Development of Antibody Therapeutics

Growth Opportunity Universe

• Growth Opportunity 1: Improved Optimization
• Growth Opportunity 1: Improved Optimization
• Growth Opportunity 2: Focus on Novel Antibody Formats
• Growth Opportunity 2: Focus on Novel Antibody Formats
• Growth Opportunity 3: Application Expansion
• Growth Opportunity 3: Application Expansion

Appendix

• Technology Readiness Levels (TRL): Explanation

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Take the Next Step
• Legal Disclaimer